CNS Pharmaceuticals (CNSP) Receivables - Other (2021 - 2022)
CNS Pharmaceuticals' (CNSP) quarterly Receivables - Other came in at $393182.0 in Q4 2022, down 40.15% YoY from $656938.0 in Q4 2021, and down 40.15% on a QoQ basis from $656938.0 in Q4 2021.
CNS Pharmaceuticals (CNSP) Receivables - Other (2021 - 2022) Analysis & Trends
CNS Pharmaceuticals (CNSP) has 2 years of Receivables - Other data on file, last reported at $393182.0 in Q4 2022.
- Quarterly Receivables - Other fell 40.15% year-over-year to $393182.0 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $393182.0 (down 40.15% YoY) and the FY2022 annual result came in at $393182.0, down 40.15% from the prior year.
- Receivables - Other eased to $393182.0 in Q4 2022, from $656938.0 in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $3.6 million in Q2 2021 to a low of $393182.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | CNS Pharmaceuticals | 2.66 Mn | -4.54 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 393,182.00 |
| Dec 31, 2022 | 393,182.00 |
| Dec 31, 2021 | 656,938.00 |
| Dec 31, 2021 | 656,938.00 |
| Jun 30, 2021 | 3.57 Mn |
| Jun 30, 2021 | 3.57 Mn |